Mission Statement, Vision, & Core Values (2026) of JiangSu WuZhong Pharmaceutical Development Co., Ltd.

Founded in 1994 and listed as 600200.SS, JiangSu WuZhong Pharmaceutical Development Co., Ltd. builds on a multi-decade track record producing generics and chemical drugs across anti-virus, anti-infection, immune regulation, anti-tumor, digestive and cardiovascular therapeutic areas while expanding into modern TCM and high-end injection filling for medical cosmetology; driven by a mission to 'forge ahead and protect all beings' and a vision to 'become a first-class enterprise in the global pharmaceutical and healthcare markets,' the Suzhou-headquartered group-recognized with the Suzhou Quality Award 2020 and ranked among the top 100 in China's chemical pharmaceutical industry for consecutive years-has diversified through strategic stakes such as its holding in Chengdu Shang-li Aesthetic Co., Ltd. (exclusive China agency for advanced Korean hyaluronic acid products) and via Jiangsu Wuzhong Pharmaceutical Industry Investment Co., Ltd., pursuing industrial investments and M&A funds to extend its footprint across the healthcare value chain.

JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) - Intro

• Founded: 1994 (Suzhou headquarters)
• Stock ticker: 600200.SS
• Awards/recognition: Suzhou Quality Award (2020); ranked among China's top 100 chemical pharmaceutical enterprises for comprehensive strength across multiple years
• Strategic holdings: major stake in Chengdu Shang-li Aesthetic Co., Ltd. (exclusive China agency for certain South Korean hyaluronic acid products)
• Investment arm: Jiangsu Wuzhong Pharmaceutical Industry Investment Co., Ltd. (focus on medical health industry investments, M&A and industrial funds)

• Product types: generics and chemical drugs, modern TCM formulations, high-end injectable filling for cosmetology and therapeutics
• Dosage forms produced: hard capsules, granules, tablets, oral solutions, injections and other standard pharmaceutical dosage forms
• Therapeutic areas: anti-virus, anti-infection, immune modulation, oncology adjuncts, gastrointestinal and cardiovascular medicines
• Markets: domestic China distribution with progressive international expansion and export initiatives

• R&D focus: development of generics, formulation optimization, bioequivalence and specialty injectables for cosmetology and therapeutics
• Manufacturing emphasis: high-end sterile filling capacity for injectable products alongside conventional solid oral dose and liquid production lines
• Quality credentials: recognized regionally for manufacturing quality (Suzhou Quality Award) and maintained compliance with pharmaceutical production standards applicable to domestic and export markets

• Product diversification: balancing established generics with growth segments (medical cosmetology, high-margin injectables)
• Vertical and financial expansion: deploying an investment vehicle to capture upstream/downstream health industry opportunities and participate in strategic M&A
• Distribution and partnerships: leveraging exclusive agency arrangements (e.g., selected South Korean cosmetic injectables) to access differentiated product lines in China

JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) - Overview

• To proactively pursue scientific and commercial progress ('forge ahead'), emphasizing innovation, pipeline expansion, and market penetration.
• To prioritize safety, quality, and broad health protection ('protect all beings'), reflecting patient-centric R&D, regulatory compliance, and product stewardship.

• Innovation emphasis: sustained R&D investment to translate new molecules and formulations into commercial products.
• Therapeutic breadth: expansion beyond core pharmaceuticals into medical cosmetology and healthcare services to address quality-of-life needs.
• Risk management and safety: robust quality systems and pharmacovigilance to ensure product efficacy and minimize harm.
• Global aspiration: building capabilities and partnerships to become a first-class global pharmaceutical and healthcare enterprise.

• Patient-first integrity - prioritizing safety, evidence-based efficacy, and transparent communication.
• Innovation with responsibility - advancing science while maintaining rigorous quality and regulatory compliance.
• Collaborative excellence - partnering with academic institutions, industry peers, and healthcare providers to accelerate impact.
• Sustainable growth - balancing commercial expansion with long-term environmental, social, and governance (ESG) considerations.
• Global mindset - building capabilities and channels to serve diverse patient populations worldwide.

• Pipeline acceleration: prioritizing high-value therapeutic classes and formulation improvements to enhance safety and patient adherence.
• Medical cosmetology expansion: leveraging dermatological expertise and regulatory pathways to capture quality-of-life markets.
• Investment portfolio: targeted minority stakes and joint ventures to gain access to complementary technologies and foreign markets.
• Quality and safety programs: upgraded GMP facilities, pharmacovigilance systems, and third-party audits to 'protect all beings.'

JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) - Mission Statement

• Deliver high-quality pharmaceutical products and healthcare services that meet international regulatory and safety standards.
• Prioritize R&D and innovation to address unmet clinical needs and expand therapeutic portfolios.
• Expand global market presence while maintaining strong domestic leadership.
• Create shared value for employees, investors, patients, and communities through ethical conduct and sustainable practices.

• Global ambition: extending the company's footprint beyond China into Asia, Europe, and other international markets.
• Quality and compliance: meeting or exceeding GMP, EMA, and other international regulatory expectations for manufacturing and product quality.
• Holistic healthcare focus: expanding into medical cosmetology, health investments, and integrated care services alongside pharmaceuticals.
• Sustainable growth: balancing revenue expansion with disciplined R&D spending and operational efficiency.

• Patient-first: decisions and investments prioritize patient safety, efficacy, and access.
• Integrity: transparent governance, regulatory compliance, and ethical commercial practices.
• Innovation: continuous improvement in drug discovery, formulation, and delivery technologies.
• Collaboration: partnerships with academic institutions, international pharma, and healthcare providers.
• Sustainability: responsible environmental practices and community health initiatives.

• Scale R&D: accelerate clinical-stage programs and biologics development while building internal capabilities.
• Market expansion: pursue regulatory approvals and strategic alliances to enter new geographies.
• Portfolio optimization: balance blockbuster generics, specialty drugs, and consumer-health offerings.
• Capital discipline: allocate CAPEX to high-return manufacturing and digital transformation projects.

JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) - Vision Statement

JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) pursues a vision to become a leading integrated pharmaceutical group delivering high-quality, accessible therapies and cutting-edge biomedical solutions that materially improve public health outcomes in China and globally. This vision is operationalized by aligning strategic investment, manufacturing excellence, and R&D capabilities behind measurable goals for product safety, efficacy, accessibility, and technological leadership.

• High quality: insistence on GMP-compliant production, strict quality-control systems and pharmacovigilance to ensure product safety and therapeutic reliability.
• Benefiting the people: prioritizing affordable access and distribution channels to expand availability of essential medicines and vaccines across urban and rural markets.
• Innovation: sustained investment in discovery, formulation, and biopharmaceutical technologies to develop differentiated therapies and biosimilars.
• Perfection: continuous process improvement, digitalization of manufacturing and operations, and ISO/ICH-aligned governance to raise operational excellence.

These core values directly inform strategic choices - from pipeline prioritization to capital allocation and partnerships with academic institutions - and are embedded in KPIs used across the company.

Operational KPIs and governance frameworks demonstrate how values translate into practice:

• Quality assurance: batch-release defect rate target <0.05% and external recall events tracked as zero-tolerance indicators.
• Access & affordability: pricing strategies and provincial procurement participation aiming to expand provincial reimbursement coverage by 10-15% annually in target therapies.
• Innovation pipeline: goal to advance 3-5 clinical-stage projects within a 3-year horizon and to increase early-stage project win-rate via collaborative research agreements.
• Continuous improvement: lean manufacturing programs targeting 8-12% OEE (overall equipment effectiveness) gains per major facility over 2 years.

Financial and operational discipline supports the values-driven roadmap: capital allocated to upgrade sterile production lines, expand cold-chain logistics for biologics, and enhance pharmacovigilance and regulatory affairs to accelerate approvals and maintain product safety standards.

For contextual history and broader corporate details see: JiangSu WuZhong Pharmaceutical Development Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money